1. Pink Sheet
  2. >>Legislation
  3. >>Elections

Republican Leaders In Congress Want To Undercut Drug Pricing Law: What’s The Opportunity?

US Mid-Term Elections And The Inflation Reduction Act

 
• By Cathy Kelly

As Republicans expand their power in Congress, experts weigh in on prospects for significant changes to the Medicare price negotiation law and what the GOP might do to hamper implementation of the program.

Biden midterms
Can President Biden and Republican leaders in Congress find common ground on drug pricing? • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock, Getty images

With Republicans projected to take control of the US House and perhaps the Senate following the mid-term elections, the biopharma industry has an opportunity to marshal Congressional sympathies to weaken the Medicare drug price negotiation program established by President Biden’s Inflation Reduction Act.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Elections

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

‘A Lot Of That, It’s Meant To Start A Conversation’: How To Work With Trump

 
• By Alaric DeArment and Jessica Merrill

Biotech execs and lobbyists try to explain the Trump Administration's policy strategy and how to thrive in it.

Bracing For RFK At HHS: Vaccine Safety Commission Likely First Step

 
• By Michael McCaughan

Robert F. Kennedy Jr. will become HHS secretary while retaining his anti-vaccine positions. His first action likely will be creating a new safety commission, which industry must hope holds off more drastic action.

Trump And Tariffs Top Generic Industry Concerns

 
• By Dave Wallace

At a lively AAM Access! conference in Florida, AAM President and CEO John Murphy acknowledged the negative effects of potential tariffs, but also suggested that the second Trump Administration could be an opportunity for the generics and biosimilars sectors to advance market reforms.

More from Legislation

US FDA Commissioner Nominee Recruiting More Hill Staff Ahead Of User Fee Reauthorization

 
• By Michael McCaughan

Republican congressional staffers could bring a wealth of experience and strong contacts with key legislators to the FDA ahead of the next user fee reauthorization process. But will Health and Human Services Department leadership interfere?

EU HTA Regulation: Companies Can Talk To National Authorities As ‘Substitute’ For EU-Level Advice

 
• By Eliza Slawther

Not all companies will be able to access joint scientific consultations under the EU Health Technology Assessment Regulation, but success is still possible for those that engage with national agencies early on, says EUCOPE’s Alexander Natz.

EU Clinical Trials Regulation Failing To Harmonize Requirements, But UK Has ‘Great Opportunity’

 
• By Eliza Slawther

The Clinical Trials Regulation was “supposed to harmonize” requirements in the EU, but instead it is giving some countries the chance to get ahead by offering faster approval timelines, notes Telethon’s head of regulatory affairs.